This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
Hang on a second…

This CME Activity has expired and is no longer available for credit.

This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

Clinical Convergence®: The Learning Pathway in Atopic Dermatitis: Maximizing Positive Outcomes for Your Patients

Clinical Convergence®: The Learning Pathway in Atopic Dermatitis: Maximizing Positive Outcomes for Your Patients

Format

Expert Perspective

Time to Complete

45 minutes

Released

April 30, 2019

Expires

August 29, 2019
Add to Queue


YOUR FEEDBACK IS IMPORTANT!

Complete the Evaluation form for this activity and be entered into a drawing for a $100* Amazon Gift card.

*The expense for this gift card is solely funded by RMEI Medical Education, LLC. No supporter funding was used for the expense of this gift card.

Maximum Credits

0.75 / AMA PRA Category 1 CreditTM

Accredited Provider

This activity is jointly provided by Postgraduate Institute for Medicine and RMEI Medical Education, LLC.

Commercial Supporter

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Program Description

Atopic dermatitis (AD) is a chronic, inflammatory disease with potentially devastating physical, psychological, and social consequences. As our understanding of the immunologic and molecular underpinnings of AD steadily improves, more options for targeted therapies are beginning to emerge. To effectively treat AD, disease control and treatment outcomes must be measured regularly, and patients must be engaged in their own care.

Intended Audience

US-based dermatology and allergy/immunology clinicians who manage patients with atopic dermatitis (AD)

Educational Objectives

After completing this activity, the participant will demonstrate the ability to:

  • Develop treatment plans for patients with AD that reflect evidence-based guidelines, use of new and emerging therapeutic options, and strategies to optimize short-term control and long-term management of the disease
  • Assess for and manage quality-of-life issues and psychosocial comorbidities in patients with AD

Conflict Of Interest Disclosure Policy

The Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty

Jonathan I. Silverberg, MD, PhD, MPH
Associate Professor, Dermatology, Preventive Medicine, and Medical Social Sciences
Northwestern University Feinberg School of Medicine
Director, Northwestern Medicine Multidisciplinary Eczema Center
Director, Patch Testing Clinic
Northwestern Memorial Hospital
Chicago, IL

Dr. Silverberg has affiliations with AbbVie, Anaptysbio, Asana, Eli Lilly, Galderma, Glenmark, Kiniksa, LEO Pharma Inc., Menlo Therapeutics Inc., Pfizer, Realm, Regeneron-Sanofi, and Roivant (Consulting Fees); Regeneron-Sanofi (Speakers’ Bureaus); and Galderma, GlaxoSmithKline, and Regeneron-Sanofi (Contracted Research).

Eric Simpson, MD, MCR
Professor of Dermatology, Department of Dermatology
Oregon Health & Science University
Portland, OR

Dr. Simpson has affiliations with AbbVie, Eli Lilly, LEO Pharma Inc., Menlo Therapeutics Inc., Pfizer, Regeneron, and Sanofi Genzyme (Consulting Fees); Eli Lilly, Glaxo Smith Kline, LEO Pharma Inc., Novartis, Regeneron Pharmaceuticals, Inc., and Roivant (Contracted Research).

Planners and Managers Disclosures

The PIM planners and managers have nothing to disclose. RMEI Medical Education, LLC planners and managers have nothing to disclose, except for Misha Mutizwa, MD, who has affiliations with Celgene (Consulting Fees, Speakers’ Bureau).

Credit

0.75

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement


In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RMEI Medical Education, LLC. The Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation Statement

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)TM  .  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

FEE INFORMATION

There is no fee for this educational activity.

Medium

Internet

Instructions

By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive up to 0.75 AMA PRA Category 1 Credit(s)TM . A statement of credit will be available to print from your user history page. Users must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity post-test and evaluation.
Physicians who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation. A copy of your certificate will be saved in your CME History on myCME.

If you would like to contact Postgraduate Institute for Medicine, please email information@pimed.com.

Rules and Regulations

This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a monthly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your email address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card. If you would like to contact RMEI, please email contact@RMEI.com.
Add to Queue